Actively Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Led by C4 Therapeutics, Inc. · Updated on 2026-03-12
100
Participants Needed
3
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
CONDITIONS
Official Title
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide signed informed consent for the study
- Age 18 years or older at the time of consent
- Documented diagnosis of multiple myeloma with measurable disease at enrollment
- Received at least 3 prior anti-myeloma regimens including an immunomodulatory drug, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy unless not available locally
- Adequate organ function
- Toxicities from prior anticancer therapies resolved to baseline or CTCAE Grade 1 or less
- Female subjects must not be pregnant, breastfeeding, or intending to become pregnant during and 30 days after treatment
- Male subjects must agree to use a condom during treatment and for 30 days after last dose
- Male subjects must not donate sperm during treatment and for 30 days after discontinuation
- Subjects must not donate blood during treatment and for 30 days after discontinuation
You will not qualify if you...
- Presence of myeloma in the central nervous system
- Diagnosis of systemic light chain amyloidosis, POEMS syndrome, or myelodysplastic syndrome
- Previous treatment with cemsidomide
- Clinically significant impaired cardiac function or cardiac disease
- Thromboembolic event within 3 months prior to enrollment
- Known malignancy other than multiple myeloma that has progressed or required treatment within past 3 years
- Uncontrolled active bacterial, fungal, or viral infection
- Inability or difficulty swallowing tablets
- Other inclusion/exclusion criteria may apply per protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Berenson Cancer Center
West Hollywood, California, United States, 90069
Actively Recruiting
2
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
START San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
S
Study Medical Officer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here